Deals in Depth: June/July 2010
Front-runners for June alliances were J&J's $586 million respiratory deal with Orexo and Bayer Schering's cancer partnership with OncoMed valued at about $540 million. Leading the pack for biopharma M&A was Grifol's $3.4 billion bid (plus $600 million in debt) for privately owned Talecris. In financings, both biopharma and device companies were busy raising private money, bringing in over $1.3 billion in June and July (compared with only $157 million in public sales).
You may also be interested in...
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.